Last updated: February 19, 2026
Summary
This litigation concerns Otsuka Pharmaceutical Co., Ltd.'s U.S. Patent No. 8,772,307 (the '307 patent), which claims a method of treating schizophrenia by administering a specific daily dosage of aripiprazole. Teva Pharmaceuticals, Inc. (Teva) seeks to market a generic version of Otsuka's Abilify Maintena, a long-acting injectable antipsychotic drug. Otsuka alleges that Teva's proposed generic product infringes the '307 patent. Teva has raised invalidity defenses, arguing that the patent claims are obvious and not novel.
What is the core dispute in this litigation?
The central issue is whether Teva's proposed generic aripiprazole extended-release injectable product infringes U.S. Patent No. 8,772,307. Otsuka contends that Teva's product, which is designed to deliver aripiprazole via injection for the treatment of schizophrenia, directly infringes the method of treatment claims in the '307 patent.
Teva disputes infringement, asserting that its product does not meet all the limitations of the asserted claims. Additionally, Teva has challenged the validity of the '307 patent, arguing that its claims are obvious and therefore invalid under 35 U.S.C. § 103 and 35 U.S.C. § 102.
What specific patent is at issue?
The patent in question is U.S. Patent No. 8,772,307, titled "Method for treating schizophrenia," filed on October 31, 2008, and issued on July 15, 2014. The patent is owned by Otsuka Pharmaceutical Co., Ltd.
The asserted claims of the '307 patent include:
- Claim 1: A method for treating schizophrenia in a subject, comprising administering to the subject an extended-release formulation of aripiprazole at a dose of at least 400 mg of aripiprazole, wherein the extended-release formulation contains 400 mg of aripiprazole, and the administration is carried out once every two weeks.
- Claim 5: A method for treating schizophrenia in a subject, comprising administering to the subject an extended-release formulation of aripiprazole at a dose of at least 800 mg of aripiprazole, wherein the extended-release formulation contains 800 mg of aripiprazole, and the administration is carried out once every four weeks.
(Source: U.S. Patent No. 8,772,307)
What is the product at the center of the dispute?
The dispute centers on Teva's proposed generic version of Otsuka's Abilify Maintena (aripiprazole extended-release injectable suspension). Abilify Maintena is indicated for the treatment of schizophrenia. The product is designed for intramuscular injection.
Otsuka alleges that Teva's generic product is intended to be administered at dosages and frequencies that would infringe the '307 patent, specifically at doses of 400 mg every two weeks and 800 mg every four weeks.
What are Teva's primary defenses?
Teva's primary defenses include non-infringement and invalidity.
Non-Infringement: Teva argues that its proposed generic product does not infringe the asserted claims of the '307 patent. This defense likely hinges on arguments that the administration of Teva's product, as contemplated by Teva, does not meet all the limitations recited in claims 1 and 5 of the '307 patent. Specific arguments would relate to dosage, frequency, or the specific extended-release formulation characteristics as applied to Teva's product.
Invalidity: Teva challenges the validity of the '307 patent on grounds of obviousness and lack of novelty.
- Obviousness (35 U.S.C. § 103): Teva contends that the claimed methods of treating schizophrenia by administering aripiprazole in extended-release formulations at specific dosages (400 mg every two weeks and 800 mg every four weeks) would have been obvious to a person of ordinary skill in the art at the time of the invention. This defense typically involves identifying prior art references that disclose elements of the claimed invention and arguing that a skilled artisan would have been motivated to combine these references to arrive at the claimed invention with a reasonable expectation of success.
- Novelty (35 U.S.C. § 102): Teva may also argue that the subject matter of the claims was not novel at the time of the invention due to prior art disclosures.
(Source: Court filings in 1:22-cv-00513)
What is the procedural history of the case?
This case was filed in the United States District Court for the District of New Jersey. Otsuka initiated the lawsuit against Teva alleging infringement of the '307 patent. Teva responded by filing an answer denying infringement and asserting affirmative defenses, including invalidity.
The case falls under the Hatch-Waxman Act, governing the abbreviated new drug application (ANDA) process for generic drugs. Otsuka, as the holder of the New Drug Application (NDA) for Abilify Maintena, listed the '307 patent in the Orange Book. Teva, by filing an ANDA, has effectively certified that its generic product does not infringe the listed patents or that the patents are invalid.
Key procedural events include:
- Complaint Filing: Otsuka filed its complaint on February 18, 2022.
- Answer and Counterclaims: Teva filed its answer, asserting non-infringement and invalidity defenses.
- Claim Construction (Markman Hearing): As is typical in patent litigation, the court will likely conduct a Markman hearing to construe the meaning of disputed claim terms. The interpretation of claim terms is critical in determining infringement and validity.
- Discovery: Parties engage in extensive discovery, including document production, interrogatories, and depositions.
- Expert Witness Reports: Both parties will rely on expert witnesses to provide testimony on technical aspects of the patent, infringement, and validity.
- Summary Judgment Motions: Parties may file motions for summary judgment on specific issues, such as non-infringement, invalidity, or other defenses.
- Trial: If the case is not resolved through settlement or summary judgment, it will proceed to trial.
(Source: U.S. District Court for the District of New Jersey, Case Docket)
What are the key technical aspects of the '307 patent and the dispute?
The '307 patent claims a method of treating schizophrenia using an extended-release formulation of aripiprazole administered at specific doses and frequencies. The technical aspects revolve around:
- Aripiprazole: This is an atypical antipsychotic medication.
- Extended-Release Formulation: This refers to a drug delivery system designed to release the active pharmaceutical ingredient (aripiprazole) over an extended period, allowing for less frequent dosing. For Abilify Maintena, this is a long-acting injectable suspension.
- Dosage and Frequency: The patent specifically claims methods involving administering 400 mg every two weeks or 800 mg every four weeks. These specific dosing regimens are crucial to the patent's claims.
- Schizophrenia Treatment: The patent's objective is to provide an improved method for managing schizophrenia.
The technical dispute will likely involve:
- Pharmacokinetics and Pharmacodynamics: How the extended-release formulation releases aripiprazole in the body and the resulting therapeutic effects.
- Formulation Science: The specific composition and properties of the extended-release vehicle that enable the claimed dosage and frequency.
- Prior Art Analysis: Examination of existing scientific literature, patents, and clinical data to determine if the claimed invention was already known or obvious. This may include analyzing prior art disclosures related to aripiprazole itself, extended-release technologies, and treatment regimens for schizophrenia.
What is the potential impact of this litigation on the generic market?
The outcome of this litigation will directly impact the entry of Teva's generic Abilify Maintena into the U.S. market.
- If Otsuka Prevails: If the court finds that Teva infringes the '307 patent and that the patent is valid, Teva's generic product will be blocked from entering the market until the patent expires or is otherwise invalidated. This would preserve Otsuka's market exclusivity for Abilify Maintena and its associated revenue stream.
- If Teva Prevails: If Teva successfully demonstrates non-infringement or invalidates the '307 patent, it could pave the way for Teva to launch its generic product. This would introduce generic competition, leading to a significant decrease in the price of aripiprazole long-acting injectable treatment and potentially increase patient access.
The specific claims at issue (400 mg every two weeks and 800 mg every four weeks) are critical. If only one of these dosing regimens is found to be infringed or if Teva can design around one but not the other, it could lead to partial market entry.
What are the key considerations for investors and stakeholders?
Investors and stakeholders should consider the following:
- Patent Strength and Validity: The strength of the '307 patent, including its prior art landscape and the potential for successful invalidity challenges, is paramount.
- Infringement Analysis: A thorough analysis of whether Teva's proposed product and intended use would literally infringe or infringe under the doctrine of equivalents is necessary.
- Claim Construction Outcomes: The court's interpretation of the patent claims during a Markman hearing can significantly alter the infringement and validity analyses.
- Litigation Timeline: The duration of the litigation and potential appeal processes can impact the timing of generic entry and therefore revenue forecasts.
- Market Dynamics: The size of the Abilify Maintena market, the demand for long-acting injectables for schizophrenia, and the potential impact of generic price reductions on market share are important factors.
- Other Patents: Otsuka may have other patents covering Abilify Maintena that could also be asserted, further complicating the landscape.
What is the commercial context of Abilify Maintena?
Abilify Maintena was developed by Otsuka and is marketed in the United States. As a long-acting injectable antipsychotic, it offers an alternative to daily oral medications for patients with schizophrenia, potentially improving adherence and treatment outcomes. The market for long-acting injectables in the antipsychotic space is competitive, and the patent protection on such therapies is a critical component of their commercial strategy. Generic entry typically leads to substantial price erosion, which can significantly impact the revenue of the innovator product.
Key Takeaways
- Otsuka Pharmaceutical Co., Ltd. is litigating U.S. Patent No. 8,772,307 against Teva Pharmaceuticals, Inc. regarding Teva's proposed generic Abilify Maintena.
- The patent claims methods of treating schizophrenia using specific extended-release aripiprazole dosages (400 mg every two weeks and 800 mg every four weeks).
- Teva's defenses include non-infringement and patent invalidity based on obviousness and lack of novelty.
- The outcome will determine the timing and availability of generic competition for Abilify Maintena, impacting market share and pricing.
- Key legal battles will focus on claim construction, prior art analysis, and the specific characteristics of Teva's generic product.
Frequently Asked Questions
-
What is the specific dosage and frequency covered by the '307 patent claims?
The asserted claims of the '307 patent cover methods of administering an extended-release formulation of aripiprazole at a dose of 400 mg every two weeks or 800 mg every four weeks.
-
What is the significance of the Markman hearing in this case?
The Markman hearing is crucial because the court's interpretation of the patent's claims will define the scope of protection. This construction directly influences whether Teva's product infringes the patent and whether the patent itself is valid against prior art.
-
Can Teva launch its generic product even if the litigation is ongoing?
Under the Hatch-Waxman Act, if Teva filed an ANDA and Otsuka sued for infringement within the 45-day window, Teva's launch is typically subject to a 30-month stay of FDA approval unless the patent litigation is resolved earlier. However, specific court orders or settlements can alter this.
-
What prior art might Teva use to challenge the '307 patent?
Teva could potentially use prior art that discloses aripiprazole, extended-release drug delivery systems, or known treatment regimens for schizophrenia. The argument would be that these prior art elements, when combined, would render the claimed methods obvious to a person skilled in the art.
-
What happens if the court finds only one of the asserted claims to be infringed or valid?
If only one claim is found to be infringed and valid, Teva's ability to launch its generic may depend on whether its product infringes that specific claim. If Teva can demonstrate that its product does not infringe the remaining valid claim, it might still be able to proceed with a launch, provided it does not infringe any other valid and enforceable patents.
Citations
[1] U.S. Patent No. 8,772,307, "Method for treating schizophrenia," issued July 15, 2014.
[2] U.S. District Court for the District of New Jersey, Case Docket for Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals, Inc., Case No. 1:22-cv-00513.
